- Trial Phase
- Phase 3 (completed)
- Time to Market
- Unknown — Phase 3 is complete, but no BLA has been filed. Regulatory engagement with FDA/Health Canada is the next step. Best-case scenario: 2-3 years if the FDA accepts a single Phase 3 study for approval under Breakthrough Therapy designation.
- Why 5/10
- Paridiprubart's pivotal Phase 3 readout (Oct 2025 / Feb 2026) has already passed with positive results. The next major catalyst is regulatory engagement with FDA/Health Canada to define the BLA filing pathway, but no hard PDUFA date has been set and no formal submission has occurred. ImpactScore reflects that the defining binary event is past; the stock still moves on newsflow but lacks a near-term hard dated binary.
The pivotal Phase 3 binary is already resolved in favor of bulls. Investors should watch for: (1) formal regulatory meetings with FDA/Health Canada to define the BLA pathway, (2) potential partnership or licensing interest given the first-in-class profile in an indication with no approved drug, and (3) the company's financing strategy — with ~$10M cash and a $150M shelf on file, dilution risk is real but the CEO's participation in the recent $3.5M PIPE signals insider conviction.
Price Chart
Executive Summary
Paridiprubart (EB05) is Edesa Biotech's lead asset — a first-in-class anti-TLR4 monoclonal antibody for Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung condition with no FDA-approved drug. In a Phase 3 trial across 278 patients, paridiprubart reduced 28-day mortality by 27% relative to placebo (p<0.001) and met all key secondary endpoints. The drug has FDA Fast Track and Breakthrough Therapy designations, and was selected by BARDA for a US government-funded platform trial. However, Edesa remains a pre-revenue clinical-stage micro-cap with ~$10M cash (as of March 2026), a ~$4M six-month burn rate, and a $150M shelf offering on file. The stock has already rerated sharply from $0.72 to the $5-11 range following the Phase 3 results. The next catalyst is regulatory engagement to define the filing pathway rather than a binary PDUFA date.
How It Works
Paridiprubart is a monoclonal antibody (a lab-made immune protein) that blocks a specific receptor called TLR4 on immune cells. TLR4 acts like an alarm bell — when it's triggered by infections or injury, it can set off a runaway inflammatory response that damages the lungs and other organs. By blocking this alarm, paridiprubart aims to calm the immune system's overreaction in conditions like ARDS, preventing the kind of collateral damage that leads to respiratory failure and death.
Trial Status
Phase 3 trial (278 patients across 38 sites in US, Canada, Colombia) met primary and secondary endpoints with statistical significance. The drug reduced 28-day mortality to 24% vs 33% for placebo (27% relative risk reduction, p<0.001). Results were consistent across subgroups including patients with acute kidney injury, sepsis, and pneumonia. An additional BARDA-funded Phase 2 platform trial in general ARDS is ongoing. The company is preparing to engage US and Canadian regulators to discuss next steps for a registrational pathway.
The Two-Sided Case
Upcoming Catalysts
- Regulatory engagement with FDA and Health Canada to define BLA filing requirements (timeline TBD)
- Additional data presentations at scientific conferences (e.g., AKI data at ERA Congress June 2026)
- BARDA-funded platform trial results in general (non-COVID) ARDS
- Potential partnership or licensing deal given first-in-class profile
- Phase 2 initiation of EB06 (vitiligo) in mid-2026 — pipeline diversification
- Q3/Q4 2026 financial results and business updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Edesa Biotech, Inc. S-3 EDSA ·Originating report